Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 7, 2007

View Archived Issues

New compounds for treating inflammatory disorders reported in recent patents

Resin increases production of NPI-0052 during fermentation of Salinispora tropica

DNA tuberculosis vaccine shows promise in cynomolgus monkey model

GSK's adjuvanted H5N1 influenza vaccine shows favorable immunogenicity and cross-reactivity

Preclinical characterization of the topical TrkA inhibitor CT-327 for the treatment of psoriasis

CXCR4 antagonist AMD-3465 prevents injury-induced neointimal formation in mice

Lundbeck and Takeda to codevelop and comarket new therapies for psychiatric disorders

Patient recruitment complete for tesamorelin confirmatory phase III trial

Lpath demonstrates preclinical efficacy of Lpathomab and begins humanization process

Dyax and Bayer Schering Pharma enter collaboration for therapeutic antibody R&D

Aradigm and Lung Rx to codevelop inhaled treprostinil using AERx Essence technology

Positive results for Next Pharmaceuticals' study of Relora

PhytoMedical reports preliminary results of preclinical diabetes trial

Cell Therapeutics to conduct full analysis of EXTEND trial after discussions with FDA

NanoViricides reports on novel class of drug candidates for influenza

Medarex and Centocor expand antibody development agreement

FDA grants fast track designation to Poniard's picoplatin for SCLC

Mircera reaches first market for CKD-associated anemia

FDA responds to Encysive's request for formal dispute resolution of Thelin NDA

Accelerated approval of Merck & Co.'s Isentress recommended by FDA Advisory Committee

Pfizer launches 5-year initiative for malaria treatment and education in three countries

Biopure and FDA discuss compassionate use protocol for Hemopure

Innocoll to sell proprietary gentamicin and bupivacaine products to EUSA Pharma

BioDelivery and Meda enter North American BEMA Fentanyl license agreement

LifeCycle begins phase I head-to-head trial of LCP-Tacro vs. Advagraf

Positive results for extension of Akela Pharma's phase IIb Fentanyl Taifun trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...